This clinical trial is focused on studying the effects of a combination of medications on several types of cancer, including liver cancer, colon cancer, pancreatic cancer, bile duct or gallbladder cancer, endometrial cancer, and esophageal cancer. The treatment being tested includes three medications: Pembrolizumab, also known by its code name MK-3475, which is given as an infusion into a vein; Lenvatinib, known as MK-7902, which is taken as a capsule by mouth; and Belzutifan, known as MK-6482, which is taken as a tablet by mouth. These medications are being studied together to see how well they work and how safe they are when used in combination.
The purpose of this study is to evaluate the safety and effectiveness of these medications when used together. Participants in the study will receive the combination of these medications and will be monitored for any side effects and how their cancer responds to the treatment. The study will take place over a period of time, during which participants will have regular check-ups and assessments to track their progress. The study aims to understand how well the combination of these medications can help in treating the different types of cancer mentioned.
Throughout the study, participants will be closely observed to ensure their safety and to gather information on how the treatment affects their cancer. The study will help researchers learn more about the potential benefits and risks of using Pembrolizumab, Lenvatinib, and Belzutifan together, which could lead to new treatment options for patients with these types of cancer in the future.



Belgium
France
Spain
The Netherlands